Rim Enhancement of Pancreatic Ductal Adenocarcinoma: Investigating the Relationship with DCE-MRI-based Radiomics and Next-generation Sequencing

Overview

Journal Front Oncol

Specialty Oncology

Date 2024 Mar 25

PMID 38525415

Authors

Moon Hyung Choi

Seung Bae Yoon

Young Joon Lee

Eun Sun Jung

Seongyong Pak

Dongyeob Han

Dominik Nickel

Affiliations

Soon will be listed here.

Abstract

Purpose: To identify the clinical and genetic variables associated with rim enhancement of pancreatic ductal adenocarcinoma (PDAC) and to develop a dynamic contrast-enhanced (DCE) MRI-based radiomics model for predicting the genetic status from next-generation sequencing (NGS).

Materials And Methods: Patients with PDAC, who underwent pretreatment pancreatic DCE-MRI between November 2019 and July 2021, were eligible in this prospective study. Two radiologists evaluated presence of rim enhancement in PDAC, a known radiological prognostic indicator, on DCE MRI. NGS was conducted for the tissue from the lesion. The Mann-Whitney U and Chi-square tests were employed to identify clinical and genetic variables associated with rim enhancement in PDAC. For continuous variables predicting rim enhancement, the cutoff value was set based on the Youden's index from the receiver operating characteristic (ROC) curve. Radiomics features were extracted from a volume-of-interest of PDAC on four DCE maps (K, K, V, and iAUC). A random forest (RF) model was constructed using 10 selected radiomics features from a pool of 392 original features. This model aimed to predict the status of significant NGS variables associated with rim enhancement. The performance of the model was validated using test set.

Results: A total of 55 patients (32 men; median age 71 years) were randomly assigned to the training (n = 41) and test (n = 14) sets. In the training set, KRAS, TP53, CDKN2A, and SMAD4 mutation rates were 92.3%, 61.8%, 14.5%, and 9.1%, respectively. Tumor size and KRAS variant allele frequency (VAF) differed between rim-enhancing (n = 12) and nonrim-enhancing (n = 29) PDACs with a cutoff of 17.22%. The RF model's average AUC from 10-fold cross-validation for predicting KRAS VAF status was 0.698. In the test set comprising 6 tumors with low KRAS VAF and 8 with high KRAS VAF, the RF model's AUC reached 1.000, achieving a sensitivity of 75.0%, specificity of 100% and accuracy of 87.5%.

Conclusion: Rim enhancement of PDAC is associated with KRAS VAF derived from NGS-based genetic information. For predicting the KRAS VAF status in PDAC, a radiomics model based on DCE maps showed promising results.

Citing Articles

Identification of SMAD4-mutated pancreatic ductal adenocarcinoma using preoperative contrast-enhanced MRI and clinical characteristics.

Li Z, Wang C, Li J, Wang X, Li X, Yu T BMC Med Imaging. 2024; 24(1):349.

PMID: 39716095 PMC: 11667844. DOI: 10.1186/s12880-024-01539-3.

References

Gillies R, Kinahan P, Hricak H . Radiomics: Images Are More than Pictures, They Are Data. Radiology. 2015; 278(2):563-77. PMC: 4734157. DOI: 10.1148/radiol.2015151169. View

Abunahel B, Pontre B, Kumar H, Petrov M . Pancreas image mining: a systematic review of radiomics. Eur Radiol. 2020; 31(5):3447-3467. DOI: 10.1007/s00330-020-07376-6. View

Hu H, Ye Z, Qin Y, Xu X, Yu X, Zhuo Q . Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications. Acta Pharmacol Sin. 2021; 42(11):1725-1741. PMC: 8563973. DOI: 10.1038/s41401-020-00584-2. View

Suzuki T, Masugi Y, Inoue Y, Hamada T, Tanaka M, Takamatsu M . KRAS variant allele frequency, but not mutation positivity, associates with survival of patients with pancreatic cancer. Cancer Sci. 2022; 113(9):3097-3109. PMC: 9459293. DOI: 10.1111/cas.15398. View

Li M, Datto M, Duncavage E, Kulkarni S, Lindeman N, Roy S . Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn. 2016; 19(1):4-23. PMC: 5707196. DOI: 10.1016/j.jmoldx.2016.10.002. View

Bartoli M, Barat M, Dohan A, Gaujoux S, Coriat R, Hoeffel C . CT and MRI of pancreatic tumors: an update in the era of radiomics. Jpn J Radiol. 2020; 38(12):1111-1124. DOI: 10.1007/s11604-020-01057-6. View

Heid I, Steiger K, Trajkovic-Arsic M, Settles M, Esswein M, Erkan M . Co-clinical Assessment of Tumor Cellularity in Pancreatic Cancer. Clin Cancer Res. 2016; 23(6):1461-1470. DOI: 10.1158/1078-0432.CCR-15-2432. View

Klaassen R, Steins A, Gurney-Champion O, Bijlsma M, van Tienhoven G, Engelbrecht M . Pathological validation and prognostic potential of quantitative MRI in the characterization of pancreas cancer: preliminary experience. Mol Oncol. 2020; 14(9):2176-2189. PMC: 7463316. DOI: 10.1002/1878-0261.12688. View

Yushkevich P, Piven J, Hazlett H, Smith R, Ho S, Gee J . User-guided 3D active contour segmentation of anatomical structures: significantly improved efficiency and reliability. Neuroimage. 2006; 31(3):1116-28. DOI: 10.1016/j.neuroimage.2006.01.015. View

10.

Ma W, Li N, Zhao W, Ren J, Wei M, Yang Y . Apparent Diffusion Coefficient and Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Pancreatic Cancer: Characteristics and Correlation With Histopathologic Parameters. J Comput Assist Tomogr. 2016; 40(5):709-16. DOI: 10.1097/RCT.0000000000000434. View

11.

Fukukura Y, Kumagae Y, Fujisaki Y, Nakamura S, Nickel M, Imai H . Extracellular volume fraction with MRI: As an alternative predictive biomarker to dynamic contrast-enhanced MRI for chemotherapy response of pancreatic ductal adenocarcinoma. Eur J Radiol. 2021; 145:110036. DOI: 10.1016/j.ejrad.2021.110036. View

12.

Jeon S, Lee J, Joo I, Lee D, Ahn S, Woo H . Magnetic resonance with diffusion-weighted imaging improves assessment of focal liver lesions in patients with potentially resectable pancreatic cancer on CT. Eur Radiol. 2018; 28(8):3484-3493. DOI: 10.1007/s00330-017-5258-1. View

13.

McIntyre C, Lawrence S, Richards A, Chou J, Wong W, Capanu M . Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma. Cancer. 2020; 126(17):3939-3949. PMC: 7424538. DOI: 10.1002/cncr.33038. View

14.

Bodalal Z, Trebeschi S, Nguyen-Kim T, Schats W, Beets-Tan R . Radiogenomics: bridging imaging and genomics. Abdom Radiol (NY). 2019; 44(6):1960-1984. DOI: 10.1007/s00261-019-02028-w. View

15.

Siegel R, Miller K, Fuchs H, Jemal A . Cancer statistics, 2022. CA Cancer J Clin. 2022; 72(1):7-33. DOI: 10.3322/caac.21708. View

16.

Chan-Seng-Yue M, Kim J, Wilson G, Ng K, Figueroa E, OKane G . Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Nat Genet. 2020; 52(2):231-240. DOI: 10.1038/s41588-019-0566-9. View

17.

Choi S, Kim Y, Min J, Cha D, Jeong W, Lee W . The value of gadoxetic acid-enhanced MRI for differentiation between hepatic microabscesses and metastases in patients with periampullary cancer. Eur Radiol. 2017; 27(10):4383-4393. DOI: 10.1007/s00330-017-4782-3. View

18.

Tang W, Liu W, Li H, Wang Q, Fu C, Wang X . Quantitative dynamic contrast-enhanced MR imaging for the preliminary prediction of the response to gemcitabine-based chemotherapy in advanced pancreatic ductal carcinoma. Eur J Radiol. 2019; 121:108734. DOI: 10.1016/j.ejrad.2019.108734. View

19.

Donati F, Boraschi P, Cervelli R, Pacciardi F, Lombardo C, Boggi U . 3 T MR perfusion of solid pancreatic lesions using dynamic contrast-enhanced DISCO sequence: Usefulness of qualitative and quantitative analyses in a pilot study. Magn Reson Imaging. 2019; 59:105-113. DOI: 10.1016/j.mri.2019.03.001. View

20.

Nauheim D, Moskal D, Renslo B, Chadwick M, Jiang W, Yeo C . KRAS mutation allele frequency threshold alters prognosis in right-sided resected pancreatic cancer. J Surg Oncol. 2022; 126(2):314-321. DOI: 10.1002/jso.26860. View